KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Assets (2016 - 2025)

Regeneron Pharmaceuticals has reported Assets over the past 17 years, most recently at $40.6 billion for Q4 2025.

  • Quarterly results put Assets at $40.6 billion for Q4 2025, up 7.41% from a year ago — trailing twelve months through Dec 2025 was $40.6 billion (up 7.41% YoY), and the annual figure for FY2025 was $40.6 billion, up 7.41%.
  • Assets for Q4 2025 was $40.6 billion at Regeneron Pharmaceuticals, up from $40.2 billion in the prior quarter.
  • Over the last five years, Assets for REGN hit a ceiling of $40.6 billion in Q4 2025 and a floor of $17.8 billion in Q1 2021.
  • Median Assets over the past 5 years was $31.4 billion (2023), compared with a mean of $31.3 billion.
  • Biggest five-year swings in Assets: surged 48.91% in 2021 and later rose 5.91% in 2025.
  • Regeneron Pharmaceuticals' Assets stood at $25.4 billion in 2021, then rose by 14.86% to $29.2 billion in 2022, then rose by 13.23% to $33.1 billion in 2023, then grew by 14.15% to $37.8 billion in 2024, then grew by 7.41% to $40.6 billion in 2025.
  • The last three reported values for Assets were $40.6 billion (Q4 2025), $40.2 billion (Q3 2025), and $38.2 billion (Q2 2025) per Business Quant data.